5月28日，科济药业-B盘中下跌5.19%，报17.18港元/股，成交额2793.5万港元。
消息面上，公司近日完成先旧后新配售2370万股，配售价为每股19.84港元，净筹约4.62亿港元，占发行前已发行股本约4.15%。配售完成后公司已发行股本增至约5.95亿股。折价配股带来的稀释效应叠加股东持仓调整，短期持续对市场情绪形成压制。此外，港股生物科技板块整体走弱，信达生物跌2.09%、康方生物跌2.0%、百济神州跌2.05%、三生制药跌4.82%，行业估值承压进一步加剧个股调整。
科济药业控股有限公司主要从事开发CAR-T细胞疗法，覆盖血液恶性肿瘤、实体瘤及自身免疫性疾病领域，主要产品包括赛恺泽、舒瑞基奥仑赛注射液及通用型CAR-T细胞产品。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.